On Wednesday morning, CND Life Sciences presented exciting new data at SLEEP 2026 from the NIH-sponsored Syn-Sleep Study, indicating that its Syn-One Test detected phosphorylated alpha-synuclein (P-SYN) in 75% of patients with idiopathic REM sleep behavior disorder (RBD). SleepWorld had a chance to sit down with CND Chief Medical Officer and […]
ARTICLES
New Study Shows Inspire Therapy Helps Reduce Hypoxic Burden
Inspire Medical Systems, Inc. participated in SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS) on June 14–17 in Baltimore, Maryland. SLEEP is the premier global forum for sleep medicine and research, jointly hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research […]
New Study: Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for Narcolepsy Type 1
New data presented by Takeda at SLEEP 2026 this week continues to build the case for oveporexton (TAK-861) as a potential disease-modifying treatment for narcolepsy type 1 (NT1). Oveporexton is designed to address the root cause of the disease, targeting the underlying orexin deficiency responsible for NT1. Results from two pivotal […]
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering
Nyxoah announced the pricing of an underwritten public offering in the United States, which includes shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union, of 55,232,558 of its ordinary shares at an offering price of $1.72 (EUR 1.48) […]
Huxley Medical Expands SANSA Diagnostic Platform with Point-of-Care Enrollment and Additional Cardiovascular Risk Marker
Huxley Medical, a commercial-stage medical technology company expanding access to sleep apnea testing across health systems, cardiology, and primary care, today introduced two additions to its SANSA® platform: SANSA GO™, a point-of-care enrollment model that enables clinics to dispense SANSA at patient visits, and hypoxic burden, an additional measure of […]
Wesper to Unveil First Multi-Tier Sleep Diagnostic Ecosystem for Personalized Sleep Care at SLEEP 2026
Wesper unveiled its multi-tier sleep diagnostic ecosystem at SLEEP 2026, the annual meeting of the Associated Professional Sleep Societies. The ecosystem brings two purpose-built diagnostic pathways, Wesper Lab and Wesper Lite, onto one platform, one patient record, and one interpretation pipeline, so physicians can match the right test to the right […]
Alkermes Presents Alixorexton and LUMRYZ Data at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
Alkermes plc announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore, MD. The company will present 26 abstracts, including posters featuring LUMRYZ® (sodium oxybate) extended-release oral […]
Jazz Pharmaceuticals to Present Data at SLEEP 2026 Highlighting Effects of Xywav for Narcolepsy and Idiopathic Hypersomnia
Jazz Pharmaceuticals announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz’s continued focus on advancing treatment for rare and difficult-to-treat sleep […]
Vitacore Announces World-First Custom-Fit CPAP Mask Following Health Canada MDL Approval
Vitacore announced that it has received a Medical Device Licence (MDL) from Health Canada for FormFit™, the world’s first fully custom-fit medical-grade silicone CPAP mask. With regulatory approval secured, Vitacore is officially launching FormFit™ across Canada, direct-to-consumer at vitacore.com/formfit and through participating sleep clinics and healthcare providers nationwide. The proprietary […]
Treating Sleep Apnea Beyond the Clinic – Daybreak Case Study
Evaluating the efficacy of a virtual care model using mandibular advancement devices for mild to moderate obstructive sleep apnea By Steven Alvarado, Peter Balacky, DDS, Edward Kim, Daniel Moradzadeh, Julieanna Gonzalez, and Martin L. Hopp, MD, PhD A prevalent sleep disorder affecting an estimated 54 million people in the […]













